Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on December 30, 2019. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Capital Market under the symbol "JAGX". The report addresses a specific regulatory event regarding the Company's continued listing status on Nasdaq.
Key Financial Metrics
This filing does not provide specific revenue, profit, cash flow, or debt figures. However, it notes that the Company currently possesses stockholders' equity of at least $5 million, a metric relevant to Nasdaq's initial listing standards.
Material Changes and Listing Status
On December 30, 2019, the Company received notice from Nasdaq that its common stock bid price had closed below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Consequently, the Company has been granted a 180-calendar-day grace period, expiring on June 29, 2020, to regain compliance. To maintain listing, the Company must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days within this period.
Outlook, Risks, and Contingencies
- Compliance Path: The Company is actively working to meet the minimum bid price requirement. If compliance is not achieved by June 29, 2020, the Company may be eligible for a second 180-day grace period if it meets other initial listing standards, including the market value of publicly held shares, in addition to the existing $5 million stockholders' equity.
- Delisting Risk: There is no assurance that the Company will regain compliance or receive an extension. Failure to meet the standards could result in the delisting of the Company's common stock from Nasdaq.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the ability to regain compliance. Actual results may differ materially due to various risks detailed in the Company's 2018 Form 10-K.
Investor Verification Checklist
- Verify the current trading price of JAGX to assess progress toward the $1.00 minimum bid price requirement.
- Confirm the Company's stockholders' equity remains above $5 million to maintain eligibility for potential extensions.
- Monitor future 8-K filings for updates on the 10-day compliance window or any further correspondence from Nasdaq.
- Review the Company's 2018 Form 10-K for detailed risk factors and financial condition not included in this 8-K.